Codexis leaps on licensing deal with GlaxoSmithKline

15 July 2014

Codexis (Nasdaq: CDXS), a developer of biocatalysts for the pharmaceutical and fine chemical industries, saw its share rocket 56% to $2.20 after revealing the signing of a platform technology license agreement with UK pharma giant GlaxoSmithKline (LSE: GSK).

Under the terms of the deal, Codexis granted GSK a license to use its proprietary CodeEvolver protein engineering platform technology in the field of human health care, marking the first time that Codexis has licensed this technology to any party in the health care field.

Codexis eligible for $25 million in first two years, then further licensing milestones

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK